✦ LIBER ✦

Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment

✍ Scribed by Fabio Stagno; Paolo Vigneri; Alessandra Cupri; Stefania Stella; Francesco Di Raimondo

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

What do kinase inhibition profiles tell

✍ Michael W. Deininger; Paul Manley 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 401 KB

First- and second-line treatment strateg

✍ T. Kühr 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 149 KB

Current Status and Perspectives of Tyros

✍ Evgeny Klyuchnikov; Nicolaus Kröger; Tim H. Brummendorf; Bettina Wiedemann; Axel 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 171 KB

Mechanisms of resistance to EGFR tyrosin

✍ Alexandra Eyzaguirre; Elizabeth Buck; Kenneth K. Iwata; John D. Haley; Mark R. M 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 248 KB

A Comparison of Methodologies for Estima

✍ Pennington, B.; Batty, A.J.; Clifton-Brown, E. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

Should epidermal growth factor receptor

✍ Rossi, Antonio; Pasquale, Raffaella; Esposito, Claudia; Normanno, Nicola 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 243 KB